Previously, we finely mapped the neutralizing epitopes recognized by foot-and-mouth disease virus (FMDV) type Asia1-specific mAb 3E11 and FMDV type O-specific mAb 8E8. In this study, we engineered recombinant FMDVs of the serotype Asia1 (rFMDVs) displaying the type Oneutralizing epitope recognized by the mAb 8E8. These epitope-inserted viruses were genetically stable and exhibited growth properties that were similar to those of their parental virus. Importantly, the recombinant virus rFMDV-C showed neutralization sensitivity to both FMDV type Asia1 and type O mAbs, as well as to polyclonal antibodies. These results indicated that this epitope-inserted virus has the potential to induce neutralizing antibodies against both FMDV type Asia1 and type O. Our results demonstrated that the G-H loop of FMDV type Asia1 effectively displays the protective neutralizing epitopes of other FMDV serotypes, making this an attractive approach for the design of novel FMDV vaccines.
Foot-and-mouth disease (FMD) is a highly contagious and economically important disease that affects cloven-hoofed animals worldwide. FMD is caused by the foot-and-mouth disease virus (FMDV), which belongs to the genus Aphthovirus within the family Picornaviridae. There are seven distinct serotypes of FMDV: O; A; C; Southern African Territories (SAT) 1, 2, and 3; and Asia1 (Grubman & Baxt, 2004) . FMDV consists of a plus-sense ssRNA genome of approximately 8500 nt surrounded by four structural proteins to form an icosahedral capsid, reviewed by Knipe & Howley (2007) . The viral RNA is translated from a single long ORF into a polyprotein. Following translation, a series of post-translational proteolytic cleavages generate the intermediate and mature structural proteins, as well as the non-structural viral proteins (Grubman et al., 1984; Robertson et al., 1985) .
The FMDV capsid has a surface-exposed, conformationally flexible G-H loop (Acharya et al., 1989; Logan et al., 1993) . In addition to being involved in viral entry (Jackson et al., 1997; Monaghan et al., 2005; Neff et al., 1998) , the VP1 G-H loop is highly immunogenic (Bittle et al., 1982; Pfaff et al., 1982) and is thought to be an important target of antibody recognition. Therefore, antibody recognition of the G-H loop is known to play a major role in the protection induced by FMDV vaccines (Borrego et al., 1995; Fischer et al., 2003; Mateu et al., 1995; Pfaff et al., 1982; Rieder et al., 1994) . Synthetic peptides representing the VP1 G-H loop sequence can elicit protective neutralizing antibody responses (Francis et al., 1990; Rowlands et al., 1983) . However, vaccination against one FMDV serotype does not usually confer any protection against other serotypes. To make this situation worse, significant antigenic differences in the variable G-H loop exist among the different serotypes and subtypes of virus strains. Despite its flexibility, the VP1 G-H loop contains a highly conserved RGD triplet that has been shown to be the receptor-binding motif (Berinstein et al., 1995) . Deletion of the RGD motif resulted in the formation of non-infectious virus particles (McKenna et al., 1995) and clearly reduced the dominant anti-FMDV B-cell epitope immune response (Frimann et al., 2007) . However, FMDV type A with a partial VP1 G-H loop deletion protected cattle from FMDV challenge (Fowler et al., 2010 (Fowler et al., , 2011 . Although studies have investigated the role of the RGD motif deletion, no attention has been devoted to the introduction of additional RGD-containing neutralizing epitope into the FMDV VP1.
An engineered poliovirus chimera expressing the gp41 epitope of human immunodeficiency virus type 1 (HIV-1) elicits broadly reactive anti-HIV-1 neutralizing antibodies (Evans et al., 1989) , suggesting that other picornaviruses might be permissive for epitope insertion. In a previous experiment, we used site-directed mutagenesis to rescue a recombinant FMDV type Asia1 with a ten-amino-acid peptide (RTSRRGDAAA) insertion into the G-H loop between VP1 aa 150 and 151. Because the insertion of the RGD-containing peptide into the FMDV type Asia1 VP1 G-H loop had no adverse effect on the generation of viable virus, we hypothesized that this insertion site of FMDV type Asia1 is permissive for the display of other serotype neutralizing epitopes or short peptides. Previously, we identified a conformational neutralizing epitope recognized by the mAb 3E11 (Wang et al., 2011) and a conserved linear neutralizing epitope recognized by the mAb 8E8 (8E8 epitope) (Yang et al., 2011) .
In this study, the VP1 of FMDV type Asia1 was selected for insertion of the FMDV type O-conserved neutralizing epitope recognized by the mAb 8E8. The selected insertion sites were supposed to display the FMDV type O-neutralizing epitope on the FMDV type Asia1 surface. With the FMDV type Asia1 infectious clone as a backbone, we constructed recombinant plasmids that contained the 8E8 epitope. Briefly, the plasmid pAsi was first digested with PstI and MluI. The restriction fragment was subsequently ligated into the pOK12-S plasmid (pOK12 with an eliminated SalI restriction site at nucleotide position 308) that was previously digested with PstI and MluI, resulting in plasmid pPM. Subsequently, a SalI restriction site at nucleotide position 3986, which corresponds to the full-length FMDV, was introduced into the pPM plasmid by site-directed mutagenesis, resulting in plasmid pPM+S. This plasmid served as the DNA template for overlapping PCR. Two primer pairs, namely, PU/AL and AU/SL (Table S1 , available in JGV Online), were used to construct pFMDV-A. PCR amplification using these primer pairs yielded fragments of 600 and 340 bp, and subsequent amplification was performed using the flanking primers PU and SL (Table S1 ). The amplified fragment encoding the epitope was digested by PstI and SalI and subsequently inserted into pPM+S. Positive clones were sequenced, digested with PstI/MluI and reintroduced into pAsi to yield recombinant plasmids. All of the recombinant plasmids were sequenced to confirm the desired insertion. The 7 aa peptide 146 GDLQVLT 152 is the minimal requirement for mAb 8E8 recognition, while the 12 aa peptide 144 ARGDLQVLTPKA 155 is the minimal unit necessary to achieve maximal binding activity for mAb 8E8. The recombinant plasmids pFMDV (139) (140) The recombinant plasmids were linearized by EcoRV and used as templates for in vitro-RNA synthesis using the RiboMAX Large Scale RNA Production Systems-T7 kit (Promega). After transfection of the in vitro-transcribed RNA into BHK-21 cells using Effectene Transfection Reagent (Qiagen), the recombinant FMDVs (rFMDVs) were detected by an indirect immunofluorescence assay (IFA) using mAb 4B2 (Yu et al., 2011) . These rFMDVs were designated rFMDV-A, rFMDV-B, rFMDV-C, rFMDV-D and rFMDV-CD (Fig. 1c) . In contrast, no viable virus was generated from the recombinant plasmids of pFMDV-E, pFMDV-F, pFMDV-G and pFMDV-H. IFA detection showed that all five rFMDVs reacted with both antibodies, mAbs 3E11 and 8E8, with the exception of the recombinant virus rFMDV-B, which failed to react with mAb 8E8 (Fig. 1c) . These results demonstrated that most of the rFMDVs appropriately displayed the 8E8 epitope on the surface of FMDV type Asia1, while the 3E11 epitope was not disturbed based on its reactivity with mAb 3E11, as observed via the IFA (Fig. 1c) . Furthermore, the tolerated insertion sites were always located within the flexible G-H loop of FMDV. Not all of the recombinant plasmids encoding the 8E8 epitope could be rescued (Fig. 1) .
To investigate the possible effects of inserting the 8E8 epitope into the G-H loop on viral growth, BHK-21 cells were infected with either rFMDVs or the parental viral strain (Asia1/YS/CHA/05) at an m.o.i. of 5, and the supernatants of the infected cells were measured for their infectious titres. This experiment was independently repeated three times and similar results were observed. As shown in Fig. 2(a) , the rFMDV-A and rFMDV-D viruses have a higher peak titre than that of the parental virus FMDV Asia1/YS/CHA/05. In contrast, the rFMDV-B, rFMDV-C and rFMDV-CD viruses replicated with slightly decreased rates compared with that of the parental strain Asia1/YS/CHA/05. Although the backbone virus Asia1/YS/ CHA/05 and the recombinant viruses replicated with different peak titres, the patterns of their growth curves were notably similar (Fig. 2a) .
To determine the stability of the recombinant viruses containing the epitopes, the rFMDVs were serially passaged 10 times in BHK-21 cells. The viruses from the fifth, seventh and tenth passages were subjected to RT-PCR, and the PCR products were purified and directly sequenced to confirm the stability of the insertion of the FMDV type Oneutralizing epitope. Sequence analysis revealed that the following viruses stably encoded the 8E8 epitope after ten passages: rFMDV-A, rFMDV-B, rFMDV-C, rFMDV-D and rFMDV-CD. Furthermore, IFA detection (Fig. 1c) and Western blot analysis (Fig. 2b, c) (Fig. 1c) . We further investigated whether these rFMDVs reacted with the mAb 8E8 and anti-FMDV type O antibodies by Western blot. The immunoblot results showed that mAb 8E8 recognized the rFMDV-C, rFMDV-D and rFMDV-CD viruses. However, the mAb 8E8 Western blot was negative for the rFMDV-A and rFMDV-B viruses (Fig. 2b) . The same results were observed when the rFMDVs were examined using anti-FMDV type O antibodies in the Western blot (Fig. 2c) . The two 12 aa epitopes that were inserted into the rFMDV-CD VP1 caused the protein to migrate more slowly through the PAGE gel than the VP1 proteins from rFMDV-C and rFMDV-D in which only one 12 aa epitope was inserted (Fig. 2b, c) . These results revealed that the length of the 8E8 epitope peptide that was inserted into the rFMDVs determines the binding activity of the mAb 8E8 antibody, as well as the anti-FMDV type O polyclonal antibodies.
Next, we examined the ability of mAbs, as well as polyclonal antibodies against FMDV type O or type Asia1, to neutralize these rFMDVs. The rFMDV-C and rFMDV-CD viruses were neutralized by both the mAb 8E8 and the anti-FMDV type O antibodies (Table 1) . It was observed that the rFMDV-D virus, containing the 144 ARGDLQVLTPKA 155 insertion between aa 139 and 140, reacted with the mAb 8E8 and anti-FMDV type O antibodies based on Western blot analysis (Fig. 2b, c) , but was not neutralized by these antibodies (Table 1) . Furthermore, the neutralization titres were different between the rFMDV strains depending on the epitope length and the insertion sites within the VP1 G-H loop. This finding suggested that neutralization occurred only when the 8E8 epitope was well-exposed on the surface of the FMDV type Asia1 particle in the correct conformation. As shown in Table 1 ). Although the recombinant virus rFMDV-CD was resistant to mAb 3E11 neutralization, it was neutralized by polyclonal anti-FMDV type Asia1 antibodies (Table 1) . Importantly, the rFMDV-C virus with the 144 ARGDLQVLTPKA 155 insertion between aa 150 and 151 was sensitive to neutralization by both mAbs 3E11 and 8E8 (Table 1 ), suggesting that the rFMDV-C virus has the potential to induce both 3E11-and 8E8-like antibodies. Moreover, rFMDV-C was neutralized by both anti-FMDV type Asia1 and type O polyclonal antibodies, further demonstrating that the rFMDV-C virus has the potential to induce neutralizing antibodies against these two important serotypes of FMDV. The efficacy of most viral vaccines is a result of their ability to elicit neutralizing antibodies (Plotkin, 2001) , and the development of immunogens that elicit neutralizing antibodies remains a high priority for the development of effective vaccines. Foreign epitope insertion into the variable regions of HIV and the simian immunodeficiency virus (SIV) Envs has been examined for its viral neutralization potential (Laird & Desrosiers, 2007; Pantophlet et al., 2009; Ren et al., 2005; Rong et al., 2007) . The incorporation of peptides into the capsid proteins of non-enveloped viruses, including human papillomavirus, cucumber mosaic virus and porcine parvovirus, has previously been employed as a method for eliciting epitope-specific antibodies (Sedlik et al., 1997; Varsani et al., 2003; Zhao & Hammond, 2005) . Previous attempts at epitope-based vaccines have shown great promise in protecting against disease in animal models (Dorrell et al., 2005; Lorin et al., 2005; Reddy et al., 2004) . For FMDV, it was demonstrated that infectious bursal disease subviral particles displaying the major FMDV antigenic site elicited a neutralizing antibody response in immunized mice (Rémond et al., 2009) . Furthermore, plant bamboo mosaic virus expressing FMDV epitopes as long as 25 aa induced protective immunity in swine (Yang et al., 2007) . The earliest report of VLPs expressing the VP1 G-H loop of FMDV in recombinant hepatitis B particles have shown to afford protection against challenge (Clarke et al., 1987) . In the current study, we explored the potential of FMDV type Asia1 to display a known protective neutralizing epitope from FMDV type O with the aim of developing an efficient viral vector platform. In particular, the recombinant virus rFMDV-C, which harbours the 12 aa insertion ( 144 ARGDLQVLTPKA 155 ) between aa 150 and 151 of VP1, demonstrated the potential to induce neutralizing antibodies against both serotypes of FMDV (Table 1 ). This result suggested that the rFMDV-C virus could be used as a bivalent FMDV vaccine candidate for further evaluation. Thus, this approach may facilitate the rational design and development of epitope-based crossprotective FMDV vaccines.
In conclusion, we engineered and characterized a number of recombinant FMDV type Asia1 viruses in which the FMDV type O neutralizing epitope was inserted into the VP1 G-H loop. Our results demonstrated that the insertion of a neutralizing epitope into the VP1 G-H loop is one promising approach for the development of an effective bivalent vaccine against both FMDV type Asia1 and FMDV type O. In addition, the ability to generate recombinant FMDVs displaying protective neutralizing epitopes is also an attractive choice for the study of virus-host interactions and may provide insights into mechanisms of FMDV neutralization by antibodies. 
